SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 250M 500M 750M FY10: 106K FY11: 803K FY12: 1.5M FY13: 12M FY14: 92.7M FY15: 147.5M FY16: 215M FY17: 302.2M FY18: 408.9M FY19: 392.8M FY20: 520.4M FY21: 579.8M FY22: 667.2M FY23: 607.5M FY24: 661.8M FY25: 719M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 250M 500M 750M FY16: 203M FY17: 287M FY18: 393.5M FY19: 376.1M FY20: 467.9M FY22: 580M FY23: 523.7M FY24: 583.9M FY25: 644.4M FY16 FY17 FY18 FY19 FY20 FY22 FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-120M -60M 0 60M 120M 180M FY10: -40.1M FY11: -37.8M FY12: -42.2M FY13: -61.9M FY14: -5.3M FY15: 20.8M FY16: 54.2M FY17: 99.5M FY18: 144.4M FY19: 148.6M FY20: 173.7M FY21: 86M FY22: 46.1M FY23: -5.3M FY24: 81.7M FY25: -62.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-100M -50M 0 50M 100M 150M FY10: -38.5M FY11: 53.8M FY12: -46.3M FY13: -92.3M FY14: -10.9M FY15: 13.9M FY16: 91.2M FY17: 57.3M FY18: 111M FY19: 113.1M FY20: 127M FY21: 53.4M FY22: 60.7M FY23: 1.3M FY24: 73.9M FY25: -38.5M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 30M 60M 90M FY16: 12M FY17: 15.2M FY18: 15.4M FY19: 16.7M FY20: 52.5M FY21: 75.1M FY22: 87.2M FY23: 83.8M FY24: 77.9M FY25: 74.6M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-60M 0 60M 120M 180M FY10: -32.5M FY11: -36.2M FY12: -47.2M FY13: -57.9M FY14: -24.5M FY15: 34.5M FY16: 66.8M FY17: 114.6M FY18: 129M FY19: 143.1M FY20: 138.4M FY21: 127.1M FY22: 116.8M FY23: 111.1M FY24: 172M FY25: 47.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-60M 0 60M 120M 180M FY10: -32.8M FY11: -36.9M FY12: -48M FY13: -59.6M FY14: -25.1M FY15: 32.4M FY16: 65.2M FY17: 112.6M FY18: 128.1M FY19: 140.4M FY20: 134.9M FY22: 116.4M FY23: 110.5M FY24: 171.2M FY25: 46M FY10 FY12 FY14 FY16 FY18 FY20 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 25M 50M 75M FY10: 1.6M FY11: 1.6M FY12: 17.4M FY13: 31.8M FY14: 42.3M FY15: 51.2M FY16: 51.7M FY17: 53.3M FY18: 54.1M FY19: 53.8M FY20: 53.7M FY21: 54.4M FY22: 61.7M FY23: 55.5M FY24: 56M FY25: 56.5M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 0.00 15.00 30.00 45.00 Q4 '11: 31.38 Q1 '12: 32.81 Q2 '12: 37.37 Q3 '12: 43.46 Q4 '12: -7.72 Q1 '13: -2.27 Q2 '13: -2.55 Q3 '13: -2.78 Q4 '13: -2.92 Q1 '14: -2.70 Q2 '14: -1.73 Q3 '14: -1.01 Q4 '14: -0.27 Q1 '15: 0.13 Q2 '15: 0.09 Q3 '15: 0.23 Q4 '15: 0.28 Q1 '16: 0.34 Q2 '16: 0.48 Q3 '16: 1.58 Q4 '16: 1.70 Q1 '17: 1.81 Q2 '17: 1.95 Q3 '17: 1.06 Q4 '17: 1.06 Q1 '18: 1.36 Q2 '18: 1.61 Q3 '18: 1.84 Q4 '18: 2.06 Q1 '19: 1.91 Q2 '19: 1.95 Q3 '19: 1.97 Q4 '19: 2.11 Q1 '20: 2.17 Q2 '20: 2.21 Q3 '20: 2.41 Q4 '20: 2.36 Q1 '21: 2.07 Q2 '21: 1.85 Q3 '21: 1.51 Q4 '21: 0.98 Q1 '22: 1.30 Q2 '22: 1.01 Q3 '22: 0.64 Q4 '22: 1.02 Q1 '23: 0.88 Q2 '23: 0.72 Q3 '23: 0.40 Q4 '23: 0.02 Q1 '24: -0.27 Q2 '24: 0.11 Q3 '24: 1.09 Q4 '24: 1.32 Q1 '25: 1.11 Q2 '25: 1.15 Q3 '25: -0.34 Q4 '25: -0.68 Q1 '26: -0.51 Q2 '26: -1.92 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.